Ann: Creso enters the African continent with cannaQIX products, page-173

First 173 Last

Share
Profile

Follow
Oscar09

26,853 Posts.

1309

27/12/19

12:01

Post #: 42137686
Share

Originally posted by Patmeate ↑

Been reading all the threads and researching CPH over the last week. Couldn’t help myself and bought a couple of parcels at 10.5 and 11. Happy to ride it down to 8.5 before I eject if need be, but with such low share liquid with less than 200m in issue it was too juicy not to have a go.

i have been looking and can’t find anything related to specifics around ability to sell/export into Europe from the memo a facility.

concerns right now for me
cash flow, but they did just raise funds so should get at least 4-6 months before they need to go again.
cash burn, although I noticed they have managed to significantly lower management expenses which is a good tick if they can put enough runs on the board.

pros
low number of shares in issue
consistently increasing revenue, With 4 new products to be sold q120 which will only fuel this further
they are already generating income
potential for more income if they can secure EU license.

im well aware it’s a gamble on CPH, but at 10c it’s tough to sit on the sidelines, fingers crossed for me and holders, but I think 10 is the bottom for now.

just my 11.5c

Expand

agree,
a few buyers seeing value here.
more detail on cost reductions would give this a real kick up imo
plenty of news to come.
plenty of cash, low SOI etc some exciting products at various stages

need to be patient around the bottom
will be plenty of churn, dont get bucked off.

CPH Price at posting: 12.0¢ Sentiment: Hold Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

IRE

Iress runs 'hot' for Wealth Within's stock tips

Failure to report prompts ASX to impose multiple company suspensions

LU7

Strong PFS numbers solidify Lithium Universe's big plans for Québec

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals